Abstract 1666P
Background
Substance use and mental health disorders significantly contribute to disparities in cancer care, particularly in urban underserved areas like the South Bronx, characterized by a substantial Latinx and Black population. This study aimed to evaluate the influence of substance use and mental illness on cancer care among newly diagnosed patients at the Lincoln Cancer Center.
Methods
A retrospective analysis was conducted on newly diagnosed cancer patients treated between January and August 2022. Various aspects of their cancer care journey were assessed, including delays in diagnosis, treatment selection, compliance with care, incidence of unscheduled emergency department/inpatient visits, rates of follow-up loss, and mortality. Substance use and mental health disorders were evaluated through electronic health record reviews and structured telephone interviews. Statistical analysis was performed using descriptive statistics and the independent samples T-test in SPSS. This study was approved by the Institutional Review Board at our hospital.
Results
The study included 208 patients, with 106 (51%) having substance use disorders, 41 (19.1%) with mental health disorders and 31 (14.9%) having both. Among patients with mental health disorders, 34% received medication and 12% had regular psychiatric care. Patients with mental health disorders but no substance use, tended to be diagnosed at later cancer stages (50% vs 41.3% at stage 4). Patient with either mental health disorders or substance use disorder has delayed cancer diagnosis from initial suspicion date (64.09 days vs 46.71 days, p = 0.154) and higher non-compliance to clinic visits (20.9% vs 14.0%, p=0.015) and higher ED visit (1.67 vs 1.27, p = 0.71), admission rate (0.98 vs 0.57, p=0.232) and mortality compared to those without, showing odds ratios of 1.203 [95% CI 0.50-2.89] although statistically insignificant due to the small sample size.
Conclusions
Patients with either mental health disorders or substance use disorder exhibited more diagnostic delays, higher non-compliance with their cancer care journey, increased ED/inpatient visits, and mortality rates. Addressing both physical and mental health is crucial for narrowing cancer disparities in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11